Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

percent of the 595 patients in the study were enrolled in the United States. African-Americans represent 16 percent of the patients enrolled and 7 percent of patients in the study are cirrhotic.

Results from the HCV SPRINT-1 study will be submitted for presentation at a major medical conference later this year.

About Boceprevir Phase III Studies

The boceprevir Phase III studies are expected to begin enrolling patients this summer. For more information about the Phase III study of boceprevir in treatment-nave patients, known as HCV SPRINT-2, and the Phase III study in patients who failed prior treatment, known as HCV RESPOND-2, please visit http://www.clinicaltrials.gov, search term boceprevir.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... WINNIPEG , March 27, 2015 /PRNewswire/ - Medicure ... Board of Directors has approved the grant of an ... management company employees and consultants of the Company pursuant ... 181,070 are set to expire on the tenth anniversary ... expire on the third anniversary of the date of ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
(Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians ... osteoarthritis and musculoskeletal diseases gathered here for the ... first time in the 17-year history of the ... topic is an emerging non-pharmaceutical protocol for enhancing ... of Wolff’s law, osteogenic loading at multiples of ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... WASHINGTON , April 18 The Federal Court ... unanimous 3-judge decision,today issued an opinion supporting the ... holding that it is entitled to renew its,constitutional ... Columbia,s AccessRx Act of 2004., Last year, ...
... April 18 Breckenridge Pharmaceutical,Inc. announced today that ... approval for the Company,s Abbreviated New Drug Application ... Activella Tablets,(Estradiol/Norethindrone Acetate 1.0mg / 0.5mg) Tablets., ... a,brand product marketed by Novo Nordisk(R), which is ...
... result of age, body composition , , FRIDAY, April 18 ... younger age or body composition may not explain why ... of creatinine than white patients, says a U.S. study ... is a standard indicator of kidney function. A higher ...
... 18 Sales leaders and,organizations that regularly ... art of motivating their sales representatives. Organizations ... personnel can use the key findings,discovered in ... &,Recognizing Top-Performing Sales People.",( http://www3.best-in-class.com/dr295.htm ), ...
... ARBOR, Mich. Right now, about half of all people ... help from it. And doctors have no definitive way to ... prescription they write. , But a University of Michigan ... more certainty to how doctors and patients choose anxiety treatments, ...
... as much as drug treatments , , FRIDAY, April 18 ... symptoms in patients with terminal cancer, according to Japanese ... included a total of 517 patients with incurable cancer ... treatment for these patients was supportive expressive group therapy, ...
Cached Medicine News:Health News:PCMA: Court of Appeals Upholds Challenge to D.C.'s PBM Fiduciary-Disclosure Law 2Health News:Muscle Mass May Not Explain High Creatinine in Black Kidney Patients 2Health News:Complementary Excerpt Available from Best Practices: Rewarding and Recognizing Top-Performing Sales People 2Health News:High anxiety? 2Health News:High anxiety? 3Health News:High anxiety? 4Health News:Talk Therapy Proves Effective for Terminal Cancer Patients 2
IGF-BP3 EIA Endocrine Function 022-IGF-E03 Insulin Growth Factor binding protein...
... Angiotensin Converting Enzyme (ACE) is an integral ... the generation of Angiotensin II as well ... many different cell types, ACE is primarily ... only an important diagnostic parameter for sarcoidosis ...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... evaluation of pancreatic -cell function is not only ... of the natural history of diabetes mellitus, but ... guide to the correct choice of treatment. Peripheral ... function because of the large and variable uptake ...
Medicine Products: